Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 112

Related Citations for PubMed (Select 23749887)

1.

Acetaminophen enhances cisplatin- and paclitaxel-mediated cytotoxicity to SKOV3 human ovarian carcinoma.

Wu YJ, Neuwelt AJ, Muldoon LL, Neuwelt EA.

Anticancer Res. 2013 Jun;33(6):2391-400.

2.

PK11195 enhances chemosensitivity to cisplatin and paclitaxel in human endometrial and ovarian cancer cells.

Takai N, Ueda T, Nishida M, Nasu K, Narahara H.

Int J Mol Med. 2010 Jan;25(1):97-103.

PMID:
19956907
3.

Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.

Yang YI, Kim JH, Lee KT, Choi JH.

Gynecol Oncol. 2011 Dec;123(3):588-96. doi: 10.1016/j.ygyno.2011.08.031. Epub 2011 Sep 25.

PMID:
21945308
4.
5.

Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism.

Ren D, Villeneuve NF, Jiang T, Wu T, Lau A, Toppin HA, Zhang DD.

Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1433-8. doi: 10.1073/pnas.1014275108. Epub 2011 Jan 4.

6.

Folic acid-coupled nano-paclitaxel liposome reverses drug resistance in SKOV3/TAX ovarian cancer cells.

Tong L, Chen W, Wu J, Li H.

Anticancer Drugs. 2014 Mar;25(3):244-54. doi: 10.1097/CAD.0000000000000047.

PMID:
24275314
7.

Preclinical high-dose acetaminophen with N-acetylcysteine rescue enhances the efficacy of cisplatin chemotherapy in atypical teratoid rhabdoid tumors.

Neuwelt AJ, Nguyen T, Wu YJ, Donson AM, Vibhakar R, Venkatamaran S, Amani V, Neuwelt EA, Rapkin LB, Foreman NK.

Pediatr Blood Cancer. 2014 Jan;61(1):120-7. doi: 10.1002/pbc.24602. Epub 2013 Aug 17.

PMID:
23956023
8.
9.

[Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].

Wang Y, Li LZ, Ye L, Niu XL, Liu X, Zhu YQ, Sun WJ, Liang YJ.

Zhonghua Fu Chan Ke Za Zhi. 2010 Sep;45(9):691-8. Chinese.

PMID:
21092551
10.
11.

Hepatocyte growth factor sensitizes human ovarian carcinoma cell lines to paclitaxel and cisplatin.

Rasola A, Anguissola S, Ferrero N, Gramaglia D, Maffe A, Maggiora P, Comoglio PM, Di Renzo MF.

Cancer Res. 2004 Mar 1;64(5):1744-50.

12.

HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition.

Selvendiran K, Ahmed S, Dayton A, Kuppusamy ML, Rivera BK, Kálai T, Hideg K, Kuppusamy P.

Cancer Biol Ther. 2011 Nov 1;12(9):837-45. doi: 10.4161/cbt.12.9.17713. Epub 2011 Nov 1.

13.

Modulation of cisplatin sensitivity in human ovarian carcinoma A2780 and SKOV3 cell lines by sulforaphane.

Hunakova L, Gronesova P, Horvathova E, Chalupa I, Cholujova D, Duraj J, Sedlak J.

Toxicol Lett. 2014 Nov 4;230(3):479-86. doi: 10.1016/j.toxlet.2014.08.018. Epub 2014 Aug 23.

PMID:
25159039
14.

A novel CRAd in combination with cisplatin enhanced the antitumor efficacy in ovarian cancer.

Zhang B, Liu Y, Zhang P, Wei Y, Yin X, Zheng J.

Int J Gynecol Cancer. 2011 Dec;21(9):1540-6. doi: 10.1097/IGC.0b013e31823105ed.

PMID:
22080895
15.

Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer.

Rosanò L, Cianfrocca R, Spinella F, Di Castro V, Natali PG, Bagnato A.

Can J Physiol Pharmacol. 2010 Jun;88(6):676-81. doi: 10.1139/Y10-053.

16.

The p53 upregulated modulator of apoptosis (PUMA) chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x(L) and Mcl-1.

Yuan Z, Cao K, Lin C, Li L, Liu HY, Zhao XY, Liu L, Deng HX, Li J, Nie CL, Wei YQ.

Mol Med. 2011;17(11-12):1262-74. doi: 10.2119/molmed.2011.00176. Epub 2011 Aug 19.

17.

Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance.

Cho JM, Manandhar S, Lee HR, Park HM, Kwak MK.

Cancer Lett. 2008 Feb 18;260(1-2):96-108. Epub 2007 Nov 26.

PMID:
18036733
18.

Apoptosis as a measure of chemosensitivity to cisplatin and taxol therapy in ovarian cancer cell lines.

Gibb RK, Taylor DD, Wan T, O'Connor DM, Doering DL, Gerçel-Taylor C.

Gynecol Oncol. 1997 Apr;65(1):13-22.

PMID:
9103385
19.

Low concentration of quercetin antagonizes the cytotoxic effects of anti-neoplastic drugs in ovarian cancer.

Li N, Sun C, Zhou B, Xing H, Ma D, Chen G, Weng D.

PLoS One. 2014 Jul 7;9(7):e100314. doi: 10.1371/journal.pone.0100314. eCollection 2014.

20.

The therapeutic potential of hepatocyte growth factor to sensitize ovarian cancer cells to cisplatin and paclitaxel in vivo.

Bardella C, Dettori D, Olivero M, Coltella N, Mazzone M, Di Renzo MF.

Clin Cancer Res. 2007 Apr 1;13(7):2191-8.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk